Xanomeline and trospium chloride Improves Cognition in Schizophrenia With Baseline Impairments, reveals study
Xanomeline and trospium chloride (KarXT), a novel M1/M4 muscarinic receptor agonist, significantly improves cognitive performance among patients with schizophrenia who have baseline cognitive impairments. This was reported by a recent study published in The American Journal of Psychiatry conducted by William P. and fellow researchers.
Earlier work, including a phase 2 trial, established that xanomeline/trospium enhances cognitive measures in a subgroup of patients who enter the trial with clinically significant baseline cognitive impairments. Phase 3 trials, recently completed, validated this observation and established xanomeline/trospium as a targeted therapy for cognitive impairment in schizophrenia, even though its established efficacy remains as an antipsychotic medication.
Methods
Data from two 5-week inpatient phase 3 trials were analyzed. These trials evaluated the efficacy of xanomeline/trospium as monotherapy in patients with acute schizophrenia. The primary endpoint was the Positive and Negative Syndrome Scale (PANSS) total score. To evaluate cognitive benefit, the statistical analysis plan included comparisons of changes in cognitive composite score between xanomeline/trospium and placebo in two groups: the full sample (N = 357) and a subgroup with clinically significant baseline cognitive impairment, defined as scores ≤1 SD below norms at baseline. Additional analyses examined the effect size in subgroups with more severe cognitive impairment (≤−1.5 SD).
Results
Full Sample Analysis: In the full sample (N = 357), there were no significant cognitive differences between xanomeline/trospium and placebo.
Cognitively Impaired Subgroup (≤−1 SD):
For the cognitively impaired subgroup (≤−1 SD), xanomeline/trospium (N = 71) significantly outperformed placebo (N = 66).
Difference between least squares means: 0.31, SE: 0.10, effect size (d) = 0.54.
Higher Threshold of Impairment (≤−1.5 SD):
The effect size increased to 0.80, which means the cognitive benefit was stronger in participants with more severe baseline impairments.
Symptom Correlation: Improvements in cognitive scores were minimally correlated with changes in PANSS total, positive, or negative symptoms in both treatment groups, which means that the cognitive benefits were independent of improvements in psychotic symptoms.
Xanomeline/trospium significantly improved cognitive performance in schizophrenia patients with baseline impairments, confirming previous phase 2 findings. The cognitive benefits, independent of psychotic symptom changes, suggest xanomeline/trospium’s potential as a novel treatment for cognitive deficits in schizophrenia. Further research is warranted to explore its long-term effects in stable patients.
Reference:
Horan, W. P., Sauder, C., Harvey, P. D., Ramsay, I. S., Yohn, S. E., Keefe, R. S. E., Davis, V. G., Paul, S. M., & Brannan, S. K. (2024). The impact of xanomeline and trospium chloride on cognitive impairment in acute schizophrenia: Replication in pooled data from two phase 3 trials. The American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.20240076
